Delayed
Nyse
21:15:01 05/07/2024 BST
|
5-day change
|
1st Jan Change
|
0.4
USD
|
0.00%
|
|
0.00%
|
+58.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
221.2
|
148.3
|
45.11
|
5.597
|
12.87
|
24.19
|
-
|
-
|
Enterprise Value (EV)
1 |
221.2
|
148.3
|
45.11
|
5.597
|
12.87
|
24.19
|
24.19
|
24.19
|
P/E ratio
|
-2.65
x
|
-4.91
x
|
-1.15
x
|
-0.2
x
|
-0.55
x
|
-0.71
x
|
-1.12
x
|
-1.12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-5.28
x
|
-1.37
x
|
-0.22
x
|
-0.51
x
|
-0.72
x
|
-0.62
x
|
-0.53
x
|
EV / FCF
|
-13,597,200
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
22,835
|
23,241
|
28,196
|
29,977
|
45,974
|
69,806
|
-
|
-
|
Reference price
2 |
9.685
|
6.380
|
1.600
|
0.1867
|
0.2800
|
0.3465
|
0.3465
|
0.3465
|
Announcement Date
|
26/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
03/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-28.08
|
-32.9
|
-25.7
|
-25.35
|
-33.4
|
-39.1
|
-45.9
|
EBIT
1 |
-22.21
|
-30.26
|
-35.46
|
-27.22
|
-25.35
|
-30.53
|
-35.6
|
-46.34
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.56
|
-30.09
|
-36.16
|
-28.25
|
-26.15
|
-44.09
|
-40.29
|
-50.89
|
Net income
1 |
-20.6
|
-30.1
|
-36.23
|
-28.32
|
-26.17
|
-44.1
|
-40.29
|
-50.89
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.660
|
-1.300
|
-1.390
|
-0.9500
|
-0.5100
|
-0.4900
|
-0.3100
|
-0.3100
|
Free Cash Flow
|
-16.26
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
03/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-14.72
|
-8.966
|
-7.154
|
-6.689
|
-13.84
|
-6.169
|
-5.18
|
-6.208
|
-5.856
|
-7.576
|
-5.272
|
-6.785
|
-7.7
|
-14.5
|
-8.7
|
-10.2
|
-
|
-
|
EBIT
1 |
-15.84
|
-9.785
|
-7.786
|
-7.324
|
-
|
-6.549
|
-5.56
|
-6.208
|
-6.073
|
-7.795
|
-5.272
|
-6.785
|
-7.064
|
-
|
-7.43
|
-7.81
|
-7.743
|
-8.394
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.73
|
-10.41
|
-8.16
|
-7.473
|
-15.63
|
-6.772
|
-5.847
|
-6.355
|
-6.403
|
-7.898
|
-5.49
|
-17.32
|
-8.306
|
-25.4
|
-8.864
|
-9.576
|
-10.33
|
-11.01
|
Net income
1 |
-15.74
|
-10.46
|
-8.169
|
-7.482
|
-15.65
|
-6.78
|
-5.886
|
-6.361
|
-6.411
|
-7.906
|
-5.491
|
-17.33
|
-8.308
|
-25.4
|
-8.867
|
-9.61
|
-10.33
|
-11.01
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6500
|
-0.3600
|
-0.2700
|
-0.2500
|
-0.5300
|
-0.2300
|
-0.2000
|
-0.2000
|
-0.1200
|
-0.1300
|
-0.0800
|
-0.2800
|
-0.0867
|
-0.3800
|
-0.0933
|
-0.0967
|
-0.0500
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/08/21
|
30/03/22
|
11/05/22
|
10/08/22
|
10/08/22
|
09/11/22
|
29/03/23
|
15/05/23
|
09/08/23
|
14/11/23
|
03/04/24
|
20/05/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-16.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
3.68
|
-
|
-
|
0.05
|
0.06
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
03/04/24
|
-
|
-
|
-
|
Last Close Price
0.3465
USD Average target price
2.167
USD Spread / Average Target +525.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.45% | 122B | | +19.57% | 112B | | -23.91% | 19.33B | | -18.45% | 16.17B | | -18.75% | 15.6B | | -49.33% | 14.65B | | +57.74% | 14.34B | | +7.13% | 14B | | +126.49% | 11.29B |
Bio Therapeutic Drugs
|